Jordi Martorell López, PhD
Head of GEVAB Group - Assistant Professor
+34932672000
RESEARCH LINES
- Correlation between arterial flow disturbances and cardiovascular disease biomarkers
- Computational fluid dynamics modelling of complex arterial environments
- Development of biocompatible artificial arteries using tissue engineering
- Stent design strategies to reduce the impact of stenting surgeries
COORDINATOR:
School of Engineering
Vascular Engineering and Applied Biomedicine Group
GEVAB's main objective is to integrate knowledge from medicine, biology, chemistry, physics, mathematics and computing in order to provide solutions to clinical needs.
LATEST PROJECTS
IMMUTOL (Advanced antigen-specific dendritic cell-based therapy to re-establish tolerance in immunemediated diseases)
IMMUTOL is the Accelerated development and validation of an advanced therapeutic drug (ATMP) based on modified VitD3
Funding Agency:
Research Group Link:
Vascular Engineering and Applied Biomedicine Group (GEVAB)
PolyCoarct (Stents poliméricos adaptables para tratar coarctación aórtica pediátrica)
Stents poliméricos adaptables para tratar coarctación aórtica pediátrica.
Funding Agency:
Research Group Link:
Vascular Engineering and Applied Biomedicine Group (GEVAB)
VasCraft (Nuevo injerto humano vascular descelularizado y re-endotelizado producido mediante ingeniería de tejidos para su uso en derivación arterial)
Desarrollo de un injerto venoso para generar un producto de terapia avanzada bajo condiciones Good Manufacturing Practice (GMP), el bioimplante VasCraft para tratar la cirugía de revascularización coronaria
Funding Agency:
Research Group Link:
Vascular Engineering and Applied Biomedicine Group (GEVAB)
LINKED NEWS
Doctoral thesis
New Endovascular Patch Implantation System
13/11/2023
Dr Alejandro Aranda recently defended his doctoral thesis at IQS, in which he designed and manufactured a new system for implanting a patch inside a human aorta that includes a guide catheter, a transport catheter, and the deployment of the patch.
READ FULL NEW
Research
New Effective Therapies for Multiple Sclerosis
11/10/2023
The IQS GEVAB group forms part of the European IMMUTOL project, which aims to develop and validate an advanced immunotherapeutic product based on tolerogenic dendritic cells for the treatment of multiple sclerosis.
READ FULL NEW
Interview
Interview with Francesc Canalejo, IQS Predoctoral Researcher
05/10/2023
Francesc Canalejo Codina, a doctoral student in the Department of Industrial Engineering at IQS, has earned a grant from the Daniel Bravo Andreu Private Foundation to conduct biomedical research at MIT.
READ FULL NEW
Research
Bypass for Heart Patients Using Donor Veins
04/07/2023
This research promoted by BST, IGTP, and IQS could lead to a therapeutic and innovative alternative that aims to obtain a human-origin biological bioimplant called VASCRAFT for coronary bypass.
READ FULL NEW
Doctoral thesis
A Bioabsorbable Patch to Treat Aortic Dissection
16/05/2022
In her doctoral thesis conducted at IQS, Dr Noemí Balà has designed a specific device to treat aortic dissection featuring mechanical properties similar to those of the artery, making it possible to improve current treatments.
READ FULL NEW
Research
Aortyx Receives €2.5 Million Euros from the European Commission’s EIC Accelerator Programme
14/02/2022
The IQS spinoff company, Aortyx, has received €2.5 million euros in "Grant first" funding through the European Innovation Council (EIC) Accelerator Programme. Also, Dr Inés Moreno received one of the prestigious Torres Quevedo Grants at the end of 2021 to conduct her research in this spinoff company.
READ FULL NEW
Research
New 3D printer at IQS to manufacture arterial models
17/12/2021
The IQS Industrial Products Engineering Laboratory equipment has been expanded with the recent incorporation of the Form 3BL 3D printer, for the manufacture of full-scale polymeric arteries.
READ FULL NEW
Research
Development of a new endovascular medical device
26/10/2021
Within the Collaboration Challenges program, Aortyx and the GEMAT group collaborate in the development and preclinical validation of a new endovascular medical device with localized and controlled release of anti-progression drugs for aneurysms.
READ FULL NEW
